A phase II trial of paclitaxel and epirubicin in advanced breast cancer

被引:0
作者
D Rischin
J Smith
M Millward
C Lewis
M Boyer
G Richardson
G Toner
H Gurney
J McKendrick
机构
[1] Division of Haematology and Medical Oncology,Department of Medical Oncology
[2] Statistical Centre,Department of Medical Oncology
[3] Peter MacCallum Cancer Institute,Department of Medical Oncology
[4] Prince of Wales Hospital,Department of Medical Oncology
[5] Royal Prince Alfred Hospital,Department of Medical Oncology
[6] Monash Medical Centre,undefined
[7] Westmead Hospital,undefined
[8] Box Hill Hospital,undefined
来源
British Journal of Cancer | 2000年 / 83卷
关键词
taxanes; anthracyclines; breast cancer; phase II;
D O I
暂无
中图分类号
学科分类号
摘要
Initial trials of paclitaxel and doxorubicin in advanced breast cancer yielded high response rates but significant cardiac toxicity was observed. In this phase II trial we investigated the efficacy and safety of paclitaxel combined with epirubicin. Patients with advanced breast cancer, performance status 0–2, measurable disease, and a normal left ventricular ejection fraction, who may have received adjuvant chemotherapy were treated with epirubicin 75 mg m–2followed by a 3-h infusion of paclitaxel 175 mg m–2repeated every 3 weeks. Forty-three eligible patients were treated at six centres. 67% patients received the maximum of six cycles. The response rate was 54% (95% CI 38–69%), 12% CR and 42% PR. Estimated median progression-free survival was 6.9 months (95% CI 5.4–10.0) and estimated median overall survival was 17.9 months (95% CI 14.2–25.7). Four patients had a decrease in the left ventricular ejection fraction (LVEF) of ≥20% of baseline value, and in two patients the LVEF decreased to below the lower limit of normal, but no patient developed clinical evidence of cardiac failure. Grade 4 neutropenia occurred in 56% cycles, but only 4% of cycles were complicated by febrile neutropenia. Grade 3 or 4 non-haematologic toxicity was uncommon. In conclusion, paclitaxel 175 mg m–2and epirubicin 75 mg m–2is a well tolerated, promising regimen for the treatment of advanced breast cancer. © 2000 Cancer Research Campaign
引用
收藏
页码:438 / 442
页数:4
相关论文
共 50 条
  • [21] Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer
    Murad, AM
    Guimaraes, RC
    Amorim, WC
    Morici, AC
    FerreiraFilho, AF
    Schwartsmann, G
    BREAST CANCER RESEARCH AND TREATMENT, 1997, 45 (01) : 47 - 53
  • [22] Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer
    A.M. Murad
    R.C. Guimaraes
    W.C. Amorim
    A.C. Morici
    A.F. Ferreira-Filho
    G. Schwartsmann
    Breast Cancer Research and Treatment, 1997, 45 : 47 - 53
  • [23] Paclitaxel: Epirubicin in metastatic breast cancer - a review
    Razis, ED
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2001, 12 (05) : 593 - 598
  • [24] EPIRUBICIN OR EPIRUBICIN AND VINDESINE IN ADVANCED BREAST-CANCER - A PHASE-III STUDY
    NIELSEN, D
    DOMBERNOWSKY, P
    SKOVSGAARD, T
    JENSEN, J
    ANDERSEN, E
    ENGELHOLM, SA
    HANSEN, M
    ANNALS OF ONCOLOGY, 1990, 1 (04) : 275 - 280
  • [25] Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
    Lehnert, M
    Mross, K
    Schueller, J
    Thuerlimann, B
    Kroeger, N
    Kupper, H
    BRITISH JOURNAL OF CANCER, 1998, 77 (07) : 1155 - 1163
  • [26] Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
    Fountzilas, G
    Kalofonos, HP
    Dafni, U
    Papadimitriou, C
    Bafaloukos, D
    Papakostas, P
    Kalogera-Fountzila, A
    Gogas, H
    Aravantinos, G
    Moulopoulos, LA
    Economopoulos, T
    Pectasides, D
    Maniadakis, N
    Siafaka, V
    Briasoulis, E
    Christodoulou, C
    Tsavdaridis, D
    Makrantonakis, P
    Razis, E
    Kosmidis, P
    Skarlos, D
    Dimopoulos, MA
    ANNALS OF ONCOLOGY, 2004, 15 (10) : 1517 - 1526
  • [27] Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
    Yi-Zhou Jiang
    Li-Ping Ge
    Xi Jin
    Lei Fan
    Min He
    Yin Liu
    Li Chen
    Wen-Jia Zuo
    Jiong Wu
    Guang-Yu Liu
    Gen-Hong Di
    Zhong-Hua Wang
    Ke-Da Yu
    Zhi-Ming Shao
    Breast Cancer Research and Treatment, 2021, 185 : 371 - 380
  • [28] Neoadjuvant paclitaxel for operable breast cancer: Multicenter phase II trial with clinical outcomes
    Kimura, Morihiko
    Sano, Muneaki
    Fujimori, Minoru
    Nakagomi, Hiroshi
    Negishi, Takeshi
    Yanagita, Yasuhiro
    Sato, Nobuaki
    ANTICANCER RESEARCH, 2008, 28 (2B) : 1239 - 1244
  • [29] Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study
    Mavroudis, D
    Alexopoulos, A
    Ziras, N
    Malamos, N
    Kouroussis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Tsavaris, N
    Potamianou, A
    Rigatos, G
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 (10) : 1249 - 1254
  • [30] Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer
    Bujanda, DA
    Sarmiento, UB
    Suárez, MAC
    Ruiz, MP
    González, MAL
    Morales, JA
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (05) : 332 - 338